A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment
Vinay S Eligar,1 Stephen C Bain2 1University Hospital of Wales, Cardiff, UK; 2Singleton Hospital, Swansea University, Swansea, UK Abstract: Sitagliptin is the first dipeptidylpeptidase-4 inhibitor to be used in the management of type 2 diabetes. It is widely used as an add-on therapy to ongoing mana...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Knjiga |
| Izdano: |
Dove Medical Press,
2013-08-01T00:00:00Z.
|
| Teme: | |
| Online pristup: | Connect to this object online. |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Primjerak 1 | Dostupno |